Idera Pharma Appoints New CMO
This article was originally published in Scrip
Executive Summary
Idera Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for cancer and rare diseases, has named Dr. Joanna Horobin senior vice president and chief medical officer. Horobin was most recently chief medical officer of Verastem Inc. and previously served as CEO of Syndax Pharmaceuticals. Prior to her positions at Verastem and Syndax, she held several roles of increasing responsibility at global pharmaceutical corporations such as Rhône-Poulenc Rorer (now Sanofi), where she spearheaded the global oncology business unit’s launches of Taxotere (docetaxel) in breast cancer and Campto/Camptosar (CPT11) for colorectal cancer. Horobin's appointment with Idera will commence on November 30, 2015.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.